Dorzagliatin (RO-5305552; HMS-5552; sinogliatin) is an investigational antidiabetic agent acting as a dual-acting glucokinase activator (GKA) that is able to improves glycaemic control and pancreatic β-cell function in type 2 diabete. As of 2022 Oct 8, Dorzagliatin gained approval from the Chinese FDA (NMPA) for treating types II diabetes. Glucokinase (GK) plays a critical role in the control of whole-body glucose homeostasis. The novel GKA, HMS5552, exerts antidiabetic effects on the liver and pancreas by improving GK activity and insulin resistance, which holds promise as a novel drug for the treatment of T2DM patients.

纯度：≥98%

CAS：1191995-00-2